Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 10mg | $55.00 | $5.50/mg | In stock | Jul 27 |
| vial | 20mg | $99.00 | $4.95/mg | In stock | Jul 27 |
| vial | 40mg | $187.00 | $4.67/mg | In stock | Jul 27 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| B-9043831-P | Jun 2026 | 99.1% | Horizon Analytical | — | Unverified2 flags | View |
| 665394 | Apr 2026 | — |
CJC-1295 and Ipamorelin acetate were not part of the April 2026 removal — both left 503A Category 2 earlier, on September 27, 2024, when their nominations were withdrawn. Ipamorelin acetate remains in 503B Category 2. Neither is in Category 1, neither is on the 503A bulks list, and neither is on the July 2026 PCAC docket, so neither is authorized for compounding.
Does Blank Peptides sell Ipamorelin?
Yes — Blank Peptides currently lists Ipamorelin in 3 variants starting at $187.00 ($4.67/mg).
Is Blank Peptides's Ipamorelin third-party tested?
Yes — Disclosed Labs has indexed 2 Certificates of Analysis for Blank Peptides's Ipamorelin, with the most recent showing 99.1% purity. Blank Peptides holds an overall trust grade of B (80/100) across all 138 COAs on file.
What is Blank Peptides's trust grade for Ipamorelin?
Blank Peptides has an overall Disclosed Labs trust grade of B (80/100), computed from 138 COAs across all peptides. The most recent Ipamorelin COA was issued by Horizon Analytical.
Where is the cheapest Ipamorelin?
As of the latest data, Peptide Supply Co. offers Ipamorelin at $2.70/mg — compare with Blank Peptides's listing at $4.67/mg. See the full Ipamorelin price comparison.
What is the FDA compounding status of Ipamorelin?
CJC-1295 and Ipamorelin acetate were not part of the April 2026 removal — both left 503A Category 2 earlier, on September 27, 2024, when their nominations were withdrawn. Ipamorelin acetate remains in 503B Category 2. Neither is in Category 1, neither is on the 503A bulks list, and neither is on the July 2026 PCAC docket, so neither is authorized for compounding. Sales tracked here are for research purposes only. Disclosed Labs does not provide medical or legal advice.
| Freedom Diagnostics |
| Endotoxin |
| Confirmed |
| View |
Disclosed Labs